Unfortunately, even with these long-term treatments for ERα+breast cancer, the probability of recurrence remains static beyondfive years following diagnosis, and consequently, many patients (30–50%)receiving prolonged endocrine therapy will still progress to advancedbreast cancer that is incurable with current treatments. Here, ESR1 is linked to breast carcinoma.